A growing body of evidence indicates that the therapeutic application of anti-CD200 treatment could potentially provide benefits in CD200-overexpressing malignancies encompassing hematopoietic tumors, such as chronic lymphocytic leukemia (CLL), as well as multiple solid tumors. This evidence concerns the gene CD200 and hematopoietic and lymphoid cell neoplasm.